Insights Into Patient Variability During Ivacaftor-Lumacaftor Therapy in Cystic Fibrosis
Background: The advent of cystic fibrosis transmembrane conductance regulator protein (CFTR) modulators like ivacaftor have revolutionised the treatment of cystic fibrosis (CF). However, due to the plethora of variances in disease manifestations in CF, there are inherent challenges in unified respon...
Saved in:
Main Authors: | Patrick O. Hanafin (Author), Isabelle Sermet-Gaudelus (Author), Matthias Griese (Author), Matthias Kappler (Author), Helmut Ellemunter (Author), Carsten Schwarz (Author), John Wilson (Author), Marsha Tan (Author), Tony Velkov (Author), Gauri G. Rao (Author), Elena K. Schneider-Futschik (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy
by: Connett GJ
Published: (2019) -
Long-Term Outcomes in Real Life of Lumacaftor-Ivacaftor Treatment in Adolescents With Cystic Fibrosis
by: Stéphanie Bui, et al.
Published: (2021) -
Clinical Efficacy and Safety of Ivacaftor/Lumacaftor Combination in Patients with Cystic Fibrosis: International Studies Review
by: Nataliya Yu. Kashirskaya, et al.
Published: (2021) -
Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?
by: Eva Choong, et al.
Published: (2022) -
CFTR Modulator Therapy with Lumacaftor/Ivacaftor Alters Plasma Concentrations of Lipid-Soluble Vitamins A and E in Patients with Cystic Fibrosis
by: Olaf Sommerburg, et al.
Published: (2021)